manufacture components of bacterial vaccines
at its Canton manufacturing
Control treatment for each fungus was left without contamination with bacterial vaccine
The collaboration with Wyeth to use Intercell's proprietary adjuvant IC31(R) in various bacterial vaccine
targets, which are in pre-clinical development, is progressing well.
The inactivated bacterial vaccine
Broncasma Berna has been used to treat chronic bronchitis and its complications, for asthma of bacterial origin, and for chronic sinusitis and rhinitis.
JPI), has signed an exclusive license agreement and entered into a three-year research and development collaboration to develop a multi-valent bacterial vaccine
employing GlycoVaxyn's bio-conjugation technology.
Syntiron received the grant of $244,479 in support of its Bacterial Vaccine
and Therapeutic Platform Technology, which includes the development of vaccines to prevent infections by Yersinia, Salmonella and Staphylococcus bacteria.
Weidong Yin, Chairman & CEO, commented, "PPV is the first bacterial vaccine
for which the Company has submitted the clinical trial application to the SFDA, representing our expansion of our R&D capabilities to include both bacterial and virus vaccines.
The vaccine consists of Live Attenuated Bacterial Vaccine
to Reduce or Inhibit Carriage and Shedding of Enterohemorrihagic Escherichia Coli in Cattle.
Lockhart has over fifteen years of experience in vaccine development and most recently was Assistant Vice President and Global Head of Bacterial Vaccine
Clinical R&D at Wyeth.
AVANT has the capability to manufacture vaccines for Phase 2 and 3 clinical testing to current Good Manufacturing Practices (cGMP) standards through its own state-of-the-art manufacturing facility for the production of live, attenuated bacterial vaccines
government and international advisory committees including the WHO/UNDP Steering Committee for Bacterial Vaccines
, the Steering Committee for Development of Pneumococcal Vaccine for the Pan American Health Organization, the Institute of Medicine Committee on the Children's Vaccine Initiative and the NIH Blue Ribbon Panel for Bioterrorism and its Implications for Biomedical Research.
AVANT plans to concentrate on building an enhanced portfolio of viral and bacterial vaccines
for global health and travelers around AVANT's core technologies and unique development and manufacturing capabilities.
This includes advancing other bacterial vaccines
in development; NicVAX(TM), a vaccine for smoking cessation; and Civacir(TM), an antibody product for the prevention of hepatitis C post-liver transplant.
The Company will concentrate its focus on building an enhanced portfolio of viral and bacterial vaccines
for global heath and travelers around the Company's core technologies, as well as its unique development and manufacturing capabilities.
AVANT's 11,000 square foot process development and pilot manufacturing facility in Fall River, MA will support the clinical development of its portfolio of bacterial vaccines
, including vaccines for biodefense, as well as continue development and product application of its patented thermo-stable preservation technology, VitriLife(R).